The current standard treatment of younger patients with mantle cell lymphoma (MCL) includes rituximab and highdose cytarabine (HD-AraC), usually followed by autologous stem cell transplantation (ASCT). This approach has improved the long-term outcome of these patients. However, no plateau in survival curves has been observed, and virtually all patients will experience disease recurrence for which no standard therapy exists (Dreyling et al, 2017). Allogeneic stem cell transplantation (AlloSCT) remains the only option with curative potential (Robinson et al, 2015; Tessoulin et al, 2016; Rule et al, 2017).
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death / Visco, Carlo; Tisi, Maria C; Evangelista, Andrea; Di Rocco, Alice; Zoellner, Anna-Katharina; Zilioli, Vittorio R; Hohaus, Stefan; Sciarra, Roberta; Re, Alessandro; Tecchio, Cristina; Chiappella, Annalisa; Morello, Lucia; Gini, Guido; Nassi, Luca; Perrone, Tommasina; Molinari, Anna L; Fabbri, Alberto; Cox, Maria C; Finolezzi, Erica; Ferrero, Simone; Puccini, Benedetta; Alvarez De Celis, Isabel; Arcari, Annalisa; Marino, Dario; Merli, Michele; Piazza, Francesco; Gentile, Massimo; Pelosini, Matteo; Loseto, Giacomo; Hermine, Olivier; Dreyling, Martin; Ruggeri, Marco; Martelli, Maurizio; Hoster, Eva; Vitolo, Umberto. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 185:5(2019), pp. 940-944. [10.1111/bjh.15643]
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death
Di Rocco, Alice;Martelli, Maurizio;
2019
Abstract
The current standard treatment of younger patients with mantle cell lymphoma (MCL) includes rituximab and highdose cytarabine (HD-AraC), usually followed by autologous stem cell transplantation (ASCT). This approach has improved the long-term outcome of these patients. However, no plateau in survival curves has been observed, and virtually all patients will experience disease recurrence for which no standard therapy exists (Dreyling et al, 2017). Allogeneic stem cell transplantation (AlloSCT) remains the only option with curative potential (Robinson et al, 2015; Tessoulin et al, 2016; Rule et al, 2017).| File | Dimensione | Formato | |
|---|---|---|---|
|
Visco_Time-progression_2018.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
125.71 kB
Formato
Adobe PDF
|
125.71 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
